Atos to acquire cyber security firm Paladion - Paris News
by Maria Thomas
Updated Jun 24, 2020
Headquartered in Reston, Virginia, Paladion was founded in 2000 and has since grown to more than 800 employees and cybersecurity experts worldwide with more than $29m turnover in 2019.
Led by CEO Rajat Mohanty, the company combines its cyber security specialists with proprietary Managed Detection & Response (MDR) platform and Atos global Security Operations Centers (SOCs) to deliver faster security outcomes.
The Paladion security delivery centres in the US, Middle East and India will join the wide network of Atos SOCs and benefit from Atos' unique go-to-market strategies.
"Their cloud-native technology will be an asset for our expansion strategies in cybersecurity and cloud solutions, providing our customers with accelerated business transformation." says Pierre Barnabe, Senior Executive Vice-President, Head of Big Data & Cybersecurity at Atos.
The acquisition, expected to close in Q4 this year, will bring MDR capabilities to the Atos portfolio.
"We believe this is an industry-defining deal, combining the scale and resources of Atos in managed security services with Paladion's cloud-delivered managed detection and response technology," said Mohanty.
Atos is a global leader in digital transformation with 110,000 employees in 73 countries and annual revenue of 12 billion euros.
Related Articles
- Optical Illusion Brain Test: If you have Sharp Eyes Find the Number 442 in 20 Secs
- London-based firm Nothing to release its Phone (2)
- Covid will continue to cause mini-waves, not become seasonal yet: Scientists
- Hackers offering crypto accounts for as low as $30 on darknet
- Reddit's new feature to allow users to share its content on other platforms
- Surgical masks can help kids fight respiratory infections: Study
- LinkedIn's new AI feature to write messages to hiring team
- Microsoft introduces Xbox Game Pass' new Friend Referral programme
- Disbursed over Rs 31 cr in claims to delivery partners in FY22-23: Swiggy
- India emerging as favourable destination for clinical trials: Report